Abstract
Tumor lysis syndrome (TLS) is a complication associated with electrolyte abnormalities that is observed in patients with acute leukemia who are receiving intense doses of chemotherapy. Forty-one patients with acute leukemia were treated with high-dose combination chemotherapy and were evaluated for TLS. A grading system developed for the evaluation of these patients was applied. Grade I tumor lysis was observed in 22 patients, grade II TLS in 2 patients and grade III in 1 patient. All patients were treated with intravenous fluids, mannitol, allopurinol and in some patients, aluminum-based antacids. Treatment for TLS prior to intensive chemotherapy reduced morbidity and mortality associated with high-dose chemotherapy for acute leukemias.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Allopurinol / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Blast Crisis
-
Female
-
Fluid Therapy
-
Humans
-
Leukemia / complications*
-
Leukemia / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / drug therapy
-
Male
-
Mannitol / therapeutic use
-
Middle Aged
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Remission Induction
-
Tumor Lysis Syndrome / epidemiology*
-
Tumor Lysis Syndrome / etiology
-
Tumor Lysis Syndrome / therapy*
Substances
-
Antineoplastic Agents
-
Mannitol
-
Allopurinol